An advanced skin cancer therapy that merges immunotherapy with mRNA vaccine technology has shown encouraging outcomes in a recent advanced trial, as stated by the pharmaceutical firms Merck and Moderna on Wednesday. Known as intismeran, the experimental treatment outperformed immunotherapy alone in diminishing melanoma recurrence and preventing cancer spread in patients who had prior melanoma surgery, the companies disclosed.
The announcement highlighted the treatment’s “statistically significant and clinically meaningful improvements.” However, medical professionals cautiously welcomed the news, acknowledging that the Phase 3 trial is ongoing, with the disclosed results stemming from an interim analysis.
Dr. Marcus Butler, a medical oncologist at Toronto’s Princess Margaret Cancer Centre, expressed optimism regarding the development, citing promising results from the Phase 2 study. He emphasized the need for caution despite the positive signs from the larger Phase 3 trial.
The companies intend to share detailed data at an oncology conference and with regulators in the future. Dr. Ramy Saleh, an associate professor of oncology at McGill University in Montreal, highlighted the challenges associated with scaling up novel treatments globally and emphasized the importance of addressing logistical and operational hurdles.
The treatment, named intismeran, combines Merck’s immunotherapy drug Keytruda with a customized mRNA vaccine from Moderna. This innovative approach utilizes tumor samples to identify abnormal proteins in cancer cells, known as neoantigens, and trains the immune system to target and eliminate these cancerous cells.
While the trial enrolled 1,137 high-risk patients with surgically removed Stage IIB-IV melanoma, concerns were raised about the potential immune stimulation effects of mRNA vaccines in general. The study’s focus on early-stage melanoma patients who had complete tumor removal may not necessarily translate to similar results for later-stage melanoma cases, underscoring the need for further research and clinical trials.